The fast-growing innovations and breakthroughs in medical technology amaze us every day. Believe it or not, you’re just a breath away to diagnose whether you’re ill or not.
The latest breakthrough in medical technology is by the US-based Pulse Health’s Revelar system which accurately detects and measures the presence of aldehydes, which are indicators of free radical damage in a body.
With this technology, need to give blood or urine tests to diagnose diseases will soon be outdated, meaning you don’t have to flinch your face or wrestle with your kid to give blood sample using needles.
The device is able to diagnose a person’s wellness or illness by tracking the damaged cells when one breathes into the tube device. After the cell damage diagnosis, the doctor can conclude which internal organ is damaged and needs an urgent treatment.
The device is currently in the registration process with the UAE’s Ministry of Health. The device, being registered in the Grade 1 category, will be rolled out in phases in the UAE in April 2012 and later in the region.
Pulse Health has appointed Pharmaplus as distributor in the UAE and the region.
Alaa Altaher, CEO of Pharmaplus, said: “We will also hold negotiations with the health authorities in the UAE under which there would be no blood tests for visa renewal by the authorised hospitals. Instead Revelar devices will be supplied to the government hospitals in order to detect any major disease among the residents who are renewing their visas or newcomers in the country.”
Pharmaplus will also hire a small sales and marketing team prior to the sale of the product in April.
He said aldehydes are evidence of cellular injury, and many are also highly toxic themselves. “The Revelar score is a measurement tool to give patients a very specific method to measure aldehydes, help reduce free radical damage and ultimately improve health. If a doctor has this data in his hand, then he will be able to prescribe appropriate antioxidants and enzymes, or give stress reduction advice and suggest appropriate exercises to alter the score and help in improving the wellness of a patient,” he said, adding that “we will roll out Revelar to the hospitals first, and then target corporates, insurance companies and health centres. Plus Health, the owners of the Revelar device, is in the process of launching other medical devices that use breathe-analysers.”
The new devices will be launched to diagnose blood pressure, cholesterol and diabetic in patients in the second phase of over the next couple of years.